Hexarelin and CJC-1295 both raise growth hormone, but they belong to different peptide classes and act on different receptors. Hexarelin is a growth hormone secretagogue (a GHRP) that works through the ghrelin/GHS receptor; CJC-1295 is a GHRH analog that works through the pituitary GHRH receptor. Because they hit complementary pathways, the two are sometimes combined in practice. Neither is FDA-approved.
Reviewed for accuracy · Last reviewed July 8, 2026The core distinction is mechanism. Hexarelin acts on the ghrelin/GHS receptor, the same target as GHRPs like ipamorelin, and in human studies released roughly twice the GH of an equal dose of GHRH. CJC-1295 acts on the GHRH receptor instead. Because the two pathways are complementary, GHRPs and GHRH analogs are sometimes paired in community practice, but that pairing is not something a controlled trial has validated here.
Their side-effect notes differ in a specific way. Hexarelin also transiently raises cortisol and prolactin and, like other GHRPs, its GH-releasing effect tends to partially desensitize with continued use. CJC-1295's reported effects are mostly local or fluid-related (injection-site irritation, flushing, water retention), drawn from a single small early-phase study, so its human safety picture is thin.
Neither has an approved dose or indication, so any figure for either traces to published studies or community practice rather than a guideline. Which, if either, is appropriate is a medical decision, and independently sourced peptides carry no guarantee of the testing a regulated product does.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.